Viehbacher (Sanofi), Russell (Shire), Scangos (Biogen) and other CEOs say the Big Pharma big brand, blockbuster drug model is done! Time to get out the forks.
PharmaGossip: Is Pharma's big brand era over? | Reuters.
Now the trend is toward developing products aimed at specialty markets -- like rare diseases, including genetic diseases. Sanofi just acquired Genzyme for that reason. Shire also focuses its development efforts in this area and has double digit growth rates and a high P/E multiple to show for it.
Now Big Pharma wants to play too. Which is great, except if everyone is after a rare disease model is it rare any longer? Being a copycat is the sincerest form of flattery until all the profits are gone.
Posted by Bruce Lehr May 16th 2011.
Comments